Novartis says study shows Gilenya benefits patients with MS

A Novartis logo is pictured on its headquarters building in MumbaiZURICH (Reuters) – Novartis said studies show its Gilenya drug helped keep patients with multiple sclerosis free of the disease. The Basel-based pharmaceutical manufacturer is relying on new products like Gilenya to offset patent expiries of key drugs such as Diovan for high blood pressure. Switching to Gilenya from interferon increased the proportion of patients disease free after one year of treatment, Novartis said on Wednesday. (Reporting by Alice Baghdjian)

Genomics and particle physics top the scientific charts

A DNA double helix in an undated artist's illustration released by the National Human Genome Research Institute to ReutersBy Ben Hirschler LONDON (Reuters) – Genomics and particle physics – offering different perspectives on the fundamental nature of life and the cosmos – are the two hottest areas of scientific research. Eight of the 21 most closely followed scientists in 2012 studied genes and their functions, while the single most-cited paper last year covered the hunt for the long-sought Higgs boson particle, according to a Thomson Reuters survey on Wednesday. …

Analysis: New cancer breakthroughs add pressure to control costs

By Deena Beasley (Reuters) – An exciting class of new cancer drugs may boost patients’ odds for survival, but healthcare providers and insurers will be under pressure to find savings elsewhere to pay for the high price tags of the new treatments. Doctors at this week’s annual meeting of the American Society of Clinical Oncology heard groundbreaking data on a new class of immune system boosters that some believe will become the main treatment for more than half of all cancers in the next 10 years. …

1 86 87 88 89 90 101